Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: Results from the cancer pain outcome research (CPOR) study group

Clinical Journal of Pain

Volumn 25, Issue 8, 2009, Pages 671-682

  Apolone, Giovanni ^a   Corli, Oscar ^a   Negri, Emanuele ^a   Mangano, Simone ^a   Montanari, Mauro ^a   Greco, Maria Teresa ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Buprenorphine; Cancer pain; Opioids; Outcome Research

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CORTICOSTEROID; OPIATE;

ADULT; ANALGESIA; ARTICLE; BONE METASTASIS; BREAST CANCER; BRIEF PAIN INVENTORY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLON CANCER; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GENITAL TRACT CANCER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HOSPICE CARE; HUMAN; ITALY; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; OPEN STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PANCREAS CANCER; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PRURITUS; QUALITY OF LIFE; RATING SCALE; RECTUM CANCER; SEDATION; SIDE EFFECT; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; VOMITING;

EID: 70349672833     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3181a38f9d     Document Type: Article

References (36)

1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437-1449.
2. World Health Organization. Cancer Pain Relief. 2nd ed. Geneva: World Health Organization; 1996.
3. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical Practice Guideline No.9 AHCPR Publication No. 94-0592. Rockville: Agency for Health Care and Research, US Department of Health and Human Services, Public Health Service; 1994.
4. Hanks GW, De Conno F, Cherny H, et al. and the members of the steering committee of the research network of the European Association for Palliative Care: Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-593.
5. Cohen MZ, Easley MK, Ellis C, et al, for the JCAHO. Cancer pain management and the JCAHO's Pain Standards. An institutional challenge. J Pain Symptom Manage. 2003;25: 519-527.
6. Di Maio M, Gridelli C, Gallo C, et al. Prevalence and management of pain in Italian patients with advanced nonsmall- cell lung cancer. Br J Cancer. 2004;90:2288-2296.
7. Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19:1985-1991.
8. Maltoni M. Opioids, pain, and fear. Ann Oncol. 2008;19:5-7.
9. Ripamonti C, De Conno F, Blumbhuber H, et al. Morphine for relief of cancer pain. Lancet. 1996;347:1262-1263.
10. Quigley C. The role of opioids in cancer pain. BMJ. 2005;331:825-829.
11. Reid CM, Gooberman-Hill R, Hanks GW. Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol. 2008;19: 44-48.
12. Luso dei farmaci in Italia. Rapporto nazionale gennaiosettembre 2007. Osservatorio Nazionale sull'impiego dei farmaci available at: http://www.agenziafarmaco.it/allegati/osmed-gs2007.pdf. Accessed on: November 12, 2008.
13. Apolone G, Mosconi P, Colombo P, et al. Il dolore nel paziente con cancro: un progetto di ricerca. Ricerca & Pratica. 2004; 20:137-143.
14. Apolone G, Mangano S, Compagnoni A, et al. A Multidisciplinary Project to improve the quality of cancer pain management in Italy. Background, methods, and preliminary results. J Ambul Care Manage. 2006;29:332-341.
15. Apolone G, Bertetto O, Caraceni A, et al. Pain in cancer An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health Qual Life Outcomes. 2006;4:78.
16. Clivio L, Tinazzi A, Mangano S, et al. The contribution of information technology: towards a better clinical data management. Drug Dev Res. 2006;67:245-250.
17. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, eds. Issue in Pain Measurement. New York: Raven Press; 1989:391-403.
18. Viscusi ER, Reynolds L, Chung F, et al. Patient-controlled transdermal fentanyl hydrochloride versus intravenous morphine pump for postoperative pain. A RCT JAMA. 2004; 291:1333-1341.
19. Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42:55-64.
20. Sweeney C, Bruera ED. Opioids side effects and management. In: Bruera ED, Portenoy RK, eds. Cancer Pain, Assessment and Management. Cambridge, UK: Cambridge University Press; 2003:150-170.
21. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27:S178-S189.
22. Sittl R, Likar P, Poulsen-Nautrup B. Equipotent doses of transdermal buprenorphine in patients with cancer and noncancer pain: results from a retrospective cohort study. Clin Ther. 2005;27:225-237.
23. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
24. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double blind, placebo controlled trial. Clin Ther. 2003;25:150-168.
25. Bohme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic. 2003;15:19.
26. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Results from a phase III, multicenter, randomized, double-blind, placebo controlled study. Clin Ther. 2004;26:1808-1820.
27. Giardina V, Invernizzi A, Baiardi P, et al. Studio pilota randomizzato per il controllo del dolore di origine neoplastica tramite somministrazione di fentanyl o buprenorfina per via transdermica. La rivista italiana di cure palliative. 2005;5:30-35.
28. Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long term control of chronic pain in cancer patients. Front Biosci. 2007;1:1291-1299.
29. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage. 2006;32:175-179.
30. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13179 patients. Curr Med Res Opin. 2005;21:1147-1158.
31. Murriel C, Falde I, Micò J, et al. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational study. Clin Ther. 2005; 27:451-462.
32. Caraceni A, Cherny N, Faisinger R, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an experts working group of the European Association of Palliative Care. J Pain Symptom Manage. 2002;23:239-255.
33. Holen JC, Polit C, Hjermstad MJ, et al. Pain assessment tools: is the content appropriate for the use in palliative care? J Pain Symptom Manage. 2006;32:567-580.
34. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
35. Sturmer T, Schneeweiss S, Avorn J, et al. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol. 2005; 162:279-289.
36. Cavuto S, Bravi F, Grassi MC, et al. Propensity score for the analysis of observational data: an introduction and an illustrative example. Drug Dev Res. 2006;67:208-216.